Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

Figures & data

Table 1 Patient characteristics and clinical evaluation at baseline

Characteristics	Cisplatin group (N=52)	Carboplatin group (N=93)	P-value
Median age (range), years	43 (26–65)	47 (27–68)	0.478
Menopausal status			0.222
Premenopausal	35 (67%)	53 (57%)
Postmenopausal	17 (33%)	40 (43%)
Clinical tumor stage			0.192
cT1	1 (2%)	9 (10%)
cT2	32 (62%)	52 (55%)
cT3	17 (33%)	24 (26%)
cT4	2 (3%)	8 (9%)
Clinical lymph node stage			0.231
cN0	3 (6%)	13 (14%)
cN1	39 (75%)	55 (59%)
cN2	6 (11%)	13 (14%)
cN3	4 (8%)	12 (13%)
Clinical TNM stage			0.831
II	27 (52%)	50 (54%)
III	25 (48%)	43 (46%)
Ki67 index			0.192
≥20%	11 (21%)	12 (13%)
<20%	41 (79%)	81 (87%)
Body mass index			0.295
≥25 kg/m^2	13 (25%)	31 (33%)
<25 kg/m^2	39 (75%)	62 (67%)

Figure 1 Kaplan–Meier disease free survival curve (A) and overall survival curve (B) of triple negative breast cancer patients treated with cisplatin or carboplatin.

Table 2 Clinical and pathological evaluation

Variables	Cisplatin group	Carboplatin group	OR (95% CI)	P-value
ypT0/is, ypN0			0.911 (0.459–1.806)	0.789
No	29 (56%)	54 (58%)
Yes	23 (44%)	39 (42%)
ypT0/is, ypN0/+			1.031 (0.523–2.034)	0.930
No	25 (48%)	44 (47%)
Yes	27 (52%)	49 (53%)
MP grade for breast			NA	0.448
MP 5	27 (52%)	49 (53%)
MP 4	8 (15%)	8 (9%)
MP 3	14 (27%)	24 (26%)
MP 2	3 (6%)	9 (10%)
MP 1	0 (0%)	3 (3%)
Clinical response after two cycles			NA	0.352
CR	3 (6%)	2 (2%)
PR	43 (82%)	84 (90%)
Overall (CR or PR)	46 (88%)	86 (92%)
SD or PD	6 (12%)	7 (8%)
Clinical response after four cycles			NA	0.570
CR	8 (15%)	11 (12%)
PR	37 (72%)	65 (70%)
Overall (CR or PR)	45 (87%)	76 (82%)
SD or PD	2 (4%)	7 (8%)

Notes: ypT0/is, ypN0: the absence of invasive carcinoma in both the breast and axilla. ypT0/is, ypN0/+: the absence of invasive carcinoma in the breast.

Abbreviations: CI, confidence interval; CR, complete response; MP, Miller-Payne; NA, not available; OR, odds ratio; PD, progressive disease; PR, partial response; SD, stable disease.

Table 3 Odds ratios for pathological complete response according to subgroups

Variables	Category	Univariable		Multivariable
		Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Arm	Cisplatin vs carboplatin	0.911 (0.459–1.806)	0.789	0.905 (0.441–1.857)	0.786
Age	<45 y vs ≥45 y	0.724 (0.371–1.414)	0.344	0.754 (0.376–1.511)	0.425
cT	cT1–2 vs cT3–4	0.620 (0.307–1.252)	0.182	0.572 (0.278–1.176)	0.129
cN	cN0–1 vs cN2–3	0.530 (0.237–1.187)	0.123	0.487 (0.213–1.112)	0.088
Ki67 index	<20% vs ≥20%	2.404 (0.887–6.512)	0.084	2.622 (0.945–7.274)	0.064

Abbreviations: CI, confidence interval; cN, clinical node stage; cT, clinical tumor stage; y, years.

Table 4 Most common adverse events reported as possibly, probably, or definitely related to treatment

Adverse event	Cisplatin group (N=52)		Carboplatin group (N=93)
	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Anemia	26 (50%)	5 (10%)	55 (59%)	8 (9%)
Febrile neutropenia	0 (0%)	3 (6%)	0 (0%)	5 (5%)
Neutropenia	21 (40%)	31 (60%)	25 (27%)	68 (73%)
Leukopenia	22 (42%)	26 (50%)	30 (32%)	55 (59%)
Thrombocytopenia	19 (37%)	3 (6%)	31 (33%)	7 (8%)
Bilirubin increased	23 (44%)	3 (6%)	37 (40%)	3 (3%)
AST increased	17 (33%)	2 (4%)	25 (27%)	2 (2%)
ALT increased	13 (25%)	1 (2%)	28 (30%)	0 (0%)
Diarrhea	8 (15%)	1 (2%)	13 (14%)	1 (1%)
Nausea/vomiting	23 (44%)	1 (2%)	38 (41%)	0 (0%)
Arthralgia/myalgia	3 (6%)	0 (0%)	9 (10%)	0 (0%)
Fatigue	26 (50%)	0 (0%)	39 (42%)	1 (1%)
Peripheral neuropathy	7 (13%)	2 (4%)	5 (5%)	0 (0%)

Abbreviations: ASL, aspartate transaminase; ALT, alanine transaminase.